NewsBenzingaTiziana Life Sciences anuncia datos principales del ensayo de fase 2a INFORM-MS con foralumab intranasal en pacientes con SPMS no activa; el ensayo cumple los dos criterios de valoración primarios Tiziana Life Sciences anuncia datos principales del ensayo de fase 2a INFORM-MS con foralumab intranasal en pacientes con SPMS no activa; el ensayo cumple los dos criterios de valoración primarios Benzinga 2026.11.02 12:11 (GMT+0) Open on Benzinga Other news APT Drops 24% in a Week, Erasing Its Autumn Rally Doubao Work: Daily Active Users Top 8 Million, Enterprise Client ARR Exceeds 2 Billion Yuan Rantizo (Nasdaq: RNTZ) Issues Letter to Shareholders Outlining Revenue-Focused American Drone Strategy After $258.8 Million Acquisition Dear Nvidia Stock Fans, Mark Your Calendars for December 10 Nvidia clarifies when it will — and won’t —keep financing neoclouds Global-E Online Stock Is Falling Wednesday: What's Going On?
Rantizo (Nasdaq: RNTZ) Issues Letter to Shareholders Outlining Revenue-Focused American Drone Strategy After $258.8 Million Acquisition